» Articles » PMID: 37542022

Survivin Degradation by Bergenin Overcomes Pemetrexed Resistance

Overview
Publisher Springer
Date 2023 Aug 4
PMID 37542022
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Chemoresistance is a primary factor for treatment failure and tumor recurrence in non-small cell lung cancer (NSCLC) patients. The oncoprotein survivin is commonly upregulated in human malignancies and is associated with poor prognosis, but its effect on carcinogenesis and chemoresistance in NSCLC is not yet evident, and to explore an effective inhibitor targeting survivin expression is urgently needed.

Methods: The protumor characteristics of survivin and antitumor activities of bergenin in NSCLC cells were examined by MTS, colony formation assays, immunoblot, immunohistochemistry, and in vivo xenograft development.

Results: Survivin was upregulated in non-small cell lung cancer (NSCLC) tissues, while its depletion inhibited NSCLC tumorigenesis. The current study focused on bergenin, identifying its effective antitumor effect on NSCLC cells both in vivo and in vitro. The results showed that bergenin could inhibit cell proliferation and induce the intrinsic pathway of apoptosis via downregulating survivin. Mechanistically, bergenin reduced the phosphorylation of survivin via inhibiting the Akt/Wee1/CDK1 signaling pathway, thus resulting in enhanced interaction between survivin and E3 ligase Fbxl7 to promote survivin ubiquitination and degradation. Furthermore, bergenin promoted chemoresistance in NSCLC cells re-sensitized to pemetrexed treatment.

Conclusions: Survivin overexpression is required for maintaining multiple malignant phenotypes of NSCLC cells. Bergenin exerts a potent antitumor effect on NSCLC via targeting survivin, rendering it a promising agent for the treatment of NSCLC.

Citing Articles

Bergenin, a bioactive flavonoid: advancements in the prospects of anticancer mechanism, pharmacokinetics and nanoformulations.

Pandey P, Lakhanpal S, Mahmood D, Kang H, Kim B, Kang S Front Pharmacol. 2025; 15():1481587.

PMID: 39834829 PMC: 11743450. DOI: 10.3389/fphar.2024.1481587.


Erianin promotes apoptosis and inhibits Akt-mediated aerobic glycolysis of cancer cells.

Han S, Chen S, Wang J, Huang S, Xiao Y, Deng G J Cancer. 2024; 15(8):2380-2390.

PMID: 38495480 PMC: 10937289. DOI: 10.7150/jca.92780.

References
1.
Arora V, Cheung H, Plenchette S, Micali O, Liston P, Korneluk R . Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem. 2007; 282(36):26202-9. DOI: 10.1074/jbc.M700776200. View

2.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

3.
Camuzi D, Aguirre Buexm L, Lourenco S, Grazziotin R, Guaraldi S, Valverde P . Body Hypomethylation Is Frequent in Tumors from the Digestive and Respiratory Tracts and Is Associated with Risk-Factor Exposure. Int J Mol Sci. 2022; 23(14). PMC: 9316635. DOI: 10.3390/ijms23147801. View

4.
Cella E, Zullo L, Marconi S, Rossi G, Coco S, Dellepiane C . Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives. Expert Opin Biol Ther. 2022; 22(10):1259-1273. DOI: 10.1080/14712598.2022.2116273. View

5.
Cesaire M, Montanari J, Curcio H, Lerouge D, Gervais R, Demontrond P . Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives. Cancers (Basel). 2022; 14(12). PMC: 9221493. DOI: 10.3390/cancers14122829. View